Evidence map›Paper›PMID 24083235›Full record

ArticleBioMed research international2013

Formulation development and stability studies of norfloxacin extended-release matrix tablets.

Paulo Renato Oliveira, Cassiana Mendes, Lilian Klein, Maximiliano da Silva Sangoi, Larissa Sakis Bernardi, Marcos Antônio Segatto Silva

Abstract read
In one paragraph

Article in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paulo Renato OliveiraPost Graduation Program in Pharmaceutical Sciences, Universidade Estadual do Centro Oeste (UNICENTRO), 85040-080 Guarapuava, PR, Brazil.
Cassiana Mendes
Lilian Klein
Maximiliano da Silva Sangoi
Larissa Sakis Bernardi
Marcos Antônio Segatto Silva

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this research was to develop a new hydrophilic matrix system containing norfloxacin (NFX). Extended-release tablets are usually intended for once-a-day administration with benefits to the patient and lower discontinuation of the therapy. Formulations were developed with hydroxypropylmethylcellulose or poly(ethylene oxide) as hydrophilic polymers, with different molecular weights (MWs) and concentrations (20 and 30%). The tablets were found to be stable (6 months at 40 ± 2°C and 75 ± 5% relative humidity), and the film-coating process is recommended to avoid NFX photodegradation. The dissolution profiles demonstrated an extended-release of NFX for all developed formulations. Dissolution curves analyzed using the Korsmeyer exponential equation showed that drug release was controlled by both drug diffusion and polymer relaxation or erosion mechanisms. A more erosion controlled system was obtained for the formulations containing lower MW and amount of polymer. With the increase in both MW and amount of polymer in the formulation, the gel layer became stronger, and the dissolution was more drug-diffusion dependent. Formulations containing intermediate MW polymers or high concentration (30%) of low MW polymers demonstrated a combination of extended and complete in vitro drug release. This way, these formulations could provide an increased bioavailability in vivo.

Indexed as

Chemistry, PharmaceuticalDelayed-Action PreparationsDrug StabilityHypromellose DerivativesMethylcelluloseNorfloxacinPolyethylene GlycolsTabletsTime FactorsDelayed-Action PreparationsHypromellose DerivativesMethylcelluloseNorfloxacinPolyethylene GlycolsTablets

Identifiers

PMID24083235
PMCPMC3780477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.